Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

CD8 alpha + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation

A technology of dendritic cells and artificial blood, applied in biochemical equipment and methods, blood/immune system cells, animal cells, etc.

Inactive Publication Date: 2004-11-03
金炫寿 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, no CD8α + Immunophenotyped DC (CD8α + DC) exists in the human body, or CD8α + DCs can be differentiated from human hematopoietic stem cells (HSCs)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD8 alpha + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
  • CD8 alpha + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation
  • CD8 alpha + lymphoid dendritic cell differentiated from human hematopoietic stem cell and a method for differentiation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1: Extraction of hematopoietic stem cells and production of dendritic cells

[0041] In order to activate peripheral blood stem cells (PBSC), granulocyte colony-stimulating factor (G-CSF, Lenograstim, chugai, Co., Tokyo, Japan) was subcutaneously injected into 10 patients with different tumor diseases (breast gland) at a dose of 300 μg / day. cancer, leukemia, lymphoma) patients. Four days after the injection, peripheral blood stem cells were extracted using a Cobe Spectra (Cobe BCT, Inc., Lakewood, CO, USA) cell separator according to the leukocyte extraction method. Using Ficoll-Hypaque (Histopaque, Sigma Chemical, St.Louis, MO, USA), according to the method of density gradient centrifugation, mononuclear cells were separated from the peripheral blood stem cells thus obtained, and washed with phosphate-buffered saline (PBS, Sigma Chemical ) washed twice. The mononuclear cells were filtered through a 30 μm nylon mesh in PBS containing 5% bovine serum albumin (B...

Embodiment 2

[0045] Example 2: Examination of the Immunophenotype of Differentiated DCs

[0046] To confirm the immunophenotype of cultured DCs, 1×10 5 Cells were reacted for 15 minutes with fluorescein isothiocyanate or phycoerythrin-labeled monoclonal antibodies against CD1a, CD3, CD4, CD8α, CD11c, CD14, CD80, CD83, CD86, HLA class I (ABC), HLA class II (DR) (Pharmingen, San Diego, CA, USA), and the resulting solution was washed with PBS, and then analyzed by flow cytometry (FACScan, Becton Dickinson).

[0047] like image 3 As shown in A and 3B, on day 7 of culture, the cells expressed CD1a, CD11c as well as CD40, CD54, CD80, CD86 and HLA class I / II. However, CD83 + , a marker of mature DC, weakly expressed. The addition of ionomycin converted CD1a and CD14 to a negative phenotype, and CD83 + Phenotyped cells increased. In addition, if Figure 4A and 4B As shown, the cells exhibit a negative phenotype for CD3 and CD4, whereas the CD8α phenotype is positive.

[0048] These resul...

Embodiment 3

[0049] Example 3: Confirmation of CD8α + DC's phagocytosis

[0050] To confirm the phagocytic ability of differentiated DCs, 2 × 10 5 DC were incubated without FBS with dextran-FITC (Sigma) for 1 hour at 37°C. Cells that had engulfed dextran were then examined by flow cytometry.

[0051] like Figure 5B and 5C As shown, CD8α + CD has a high phagocytic capacity. In addition, on the 14th day of culture, the phagocytic ability was further enhanced. The control experiment (5A) at 4°C shows the observed CD8α of the present invention + The phagocytic activity of CD is real and not an artifact produced by the measurement conditions.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Lymphoid dendritic cells with immunophenotype CD8alpha+ can be produced by a method which comprises culturing human hematopoietic stem cells in a medium containing GM-CSF, followed by culturing in a medium containing IFN-Upsilon, the lymphoid dendritic cells being useful in various immunotherapies.

Description

technical field [0001] The present invention relates to lymphoid dendritic cells differentiated from human hematopoietic stem cells, a method for differentiating lymphoid dendritic cells from human hematopoietic stem cells, and a pharmaceutical composition containing lymphoid dendritic cells as an active ingredient for immunotherapy. Background technique [0002] Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that coordinate various immune responses against specific antigens and simultaneously suppress autoimmune responses by eliminating potentially autoreactive T cells. [0003] Murine DCs can be subdivided into at least two distinct subtypes, myeloid DS and lymphoid DCs, based on their anatomical localization, transplantation experiments, and cell surface phenotype. have CD11c + , MHCII + , CD4 + , CD8α - DCs with a cell surface phenotype known as CD8α - Myeloid DC, which can be derived from bone marrow precursor cells, has CD11c + , MHCII + , CD4 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/12A61K35/14A61K35/28A61K38/00A61K38/20A61K38/21A61P31/06A61P31/12A61P31/18A61P35/00A61P37/00A61P37/04C12N5/0784
CPCA61K2035/124A61K38/208C12N2501/22A61K2039/5154C12N5/0639A61K38/217C12N2501/24A61P31/06A61P31/12A61P31/18A61P35/00A61P37/00A61P37/02A61P37/04C12N5/0634C12N5/0647
Inventor 金炫寿李京福金孝哲
Owner 金炫寿
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com